🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against superbug strains of the infection, according to health experts.

A Worldwide Health Concern

Cases of gonorrhoea are on the rise around the world, with figures suggesting more than 82 million infections each year. Notably increased rates are seen in the African continent and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the reality of rising global incidence, the spread of superbugs and the very limited therapeutic options at this time.”

Health officials are deeply concerned about the increase in drug-resistant strains. The global health body has classified it as a "priority pathogen". Ongoing monitoring found that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Approval

One new antibiotic, also known as Nuzolvence, was authorized by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts anticipate that targeted use of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, also received approval in close succession. This treatment, which is also used to treat UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This approval signifies a significant shift in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Outcomes and Global Access

Based on data detailed in a major medical journal, the new drug cured over nine in ten of uncomplicated infections. This puts it on an comparable level with the existing first-line therapy, which uses a dual-drug approach. The research involved hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Clinicians treating patients have expressed optimism. Having a easy-to-administer therapy like this is described as a "game-changer" for public health efforts. This is deemed vital to reduce the burden of the infection for individuals and to stop the proliferation of untreatable gonorrhoea around the world.